Memo Therapeutics
CHEntry
2024
Hold
2yr
Exit
2026
Who owns Memo Therapeutics?
Memo Therapeutics was owned by Ysios Capital Partners through Ysios BioFund III (2020 vintage) from 2024 to 2026, exited via Trade Sale. Across its history, Memo Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.
Buyer identity available on Pro.
Hand-verified · updated 2026-08-03
Most recent investor
Ysios Capital PartnersYsios BioFund III · 2020 · Life Sciences VC
2 ownership periods · full history below
Key facts
Key takeaways
- ·Fully exited in 2026.
- ·Average hold across 2 realized cycles: 5 years.
Ownership history
2 ownership periods · co-invest detected
Exited
Last exited in 2026 to .
Co-invest · 2 holders · 2018 · 2026
Sobera CapitalExited 2026
2018 · 2026(8yr) · Sobera Capital Fund IV · 2017 · Secondaries
Trade Sale · to
MOIC
–
Ysios Capital PartnersExited 2026
2024 · 2026(2yr) · Ysios BioFund III · 2020 · Life Sciences VC
Trade Sale · to
MOIC
–
More from Ysios BioFund III
Other portfolio companies in the same fund.
US
More PE-backed in Biotech
Comparable biotech deals from other GPs.
UK
FranceTrack Memo Therapeutics
Save this record to your watchlist and pick up your research where you left off. No spam.
Get the full record on Memo Therapeutics.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
Already a member? Sign in
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue